PCSK9 and diabetes mellitus: In accordance with that, clinical treatment with PCSK-9 antibodies or ezetimibe reducing LDL-cholesterol extracellularly or by liver selective action, like bempedoic acid or inclisiran, were neutral regarding diabetes risk [12, 13].